Claims
- 1. A compound of formula II:
- 2. The compound of claim 1, wherein the alkyl portion of R1 has from about 2 to about 6 carbons.
- 3. The compound of claim 1, wherein R1, W and X are selected as in (i) only.
- 4. The compound of claim 1, wherein R1, W and X are selected as in (ii) only.
- 5. The compound of claim 1, wherein R1, W and X are selected as in (iii) only.
- 6. The compound of claim 1, wherein R2 is isobutyl, benzyl or —CH2CH2SO2CH3.
- 7. The compound of claim 3, wherein W is 4-methylpiperazinyl or morpholino.
- 8. The compound of claim 3, wherein R1 is 4-hydroxybenzyl or 2-phenyl-1-ethyl.
- 9. The compound of claim 4, wherein W is aryl, heteroaryl or heterocyclyl.
- 10. The compound of claim 9, wherein W is phenyl.
- 11. The compound of claim 4, wherein R1 is 4-hydroxybenzyl or 2-phenyl-1-ethyl.
- 12. The compound of claim 5, wherein W is alkyl, aralkyl, aryl or bicyclic alkyl.
- 13. The compound of claim 12, wherein W is benzyl.
- 14. The compound of claim 5, wherein R1 is 4-hydroxybenzyl or 2-phenyl-1-ethyl.
- 15. The compound of claim 1 selected from the group consisting of N-(N-(4-methylpiperazinylcarbonyl)leucyl)tyrosinal, (S)-2-(N-(4-methylpiperazinylcarbonyl)leucyl)amino-4-phenylbutanal, N-(N-(morpholinocarbonyl)leucyl)tyrosinal, (S)-2-(N-(phenylsulfonyl)-leucyl)amino-4-phenylbutanal, N-(N-(phenylsulfonyl)leucyl)tyrosinal, (S)-2-(N-(morpholinocarbonyl)phenylalanyl)amino-4-phenylbutanal, (S)-2-(N-(phenylsulfonyl)phenylalanyl)amino-4-phenylbutanal, N-(N-(morpholino-carbonyl)phenylalanyl)tyrosinal, N-(N-(4-methylpiperazinylcarbonyl)phenylalanyl)tyrosinal, (S)-2-(N-(4-methylpiperazinylcarbonyl)phenylalanyl)amino-4-phenylbutanal, N-(N-(phenylsulfonyl)phenylalanyl)tyrosinal, (S)-2-(N-(benzyloxycarbonyl)leucyl)amino-4-phenylbutanal and (S)-2-(N-(morpholinocarbonyl)leucyl)amino-4-phenylbutanal.
- 16. The compound of claim 1 selected from the group consisting of (S)-2-(N-(4-methylpiperazinylcarbonyl)leucyl)amino-4-phenylbutanal, (S)-2-(N-(phenylsulfonyl)leucyl)amino-4-phenylbutanal, (S)-2-(N-(morpholinocarbonyl)phenylalaninyl)amino-4-phenylbutanal, (S)-2-(N-(phenylsulfonyl)phenylalaninyl)amino-4-phenylbutanal, (S)-2-(N-(4-methylpiperazinylcarbonyl)phenylalaninyl)amino-4-phenylbutanal, (S)-2-(N-(benzyloxycarbonyl)leucyl)amino-4-phenylbutanal and (S)-2-(N-(morpholinocarbonyl)leucyl)amino-4-phenylbutanal.
- 17. The compound of claim 1 selected from the group consisting of (S)-2-(N-(4-methylpiperazinylcarbonyl)leucyl)amino-4-phenylbutanal, (S)-2-(N-(phenylsulfonyl)leucyl)amino-4-phenylbutanal, (S)-2-(N-(morpholinocarbonyl)phenylalaninyl)amino-4-phenylbutanal, (S)-2-(N-(phenylsulfonyl)phenylalaninyl)amino-4-phenylbutanal, (S)-2-(N-(4-methylpiperazinylcarbonyl)phenylalaninyl)amino-4-phenylbutanal and (S)-2-(N-(morpholinocarbonyl)leucyl)amino-4-phenylbutanal.
- 18. A compound of formula III:
- 19. The compound of claim 18, wherein R1 is selected as in (i) only.
- 20. The compound of claim 18, wherein R1 is selected as in (ii) only.
- 21. The compound of claim 18, wherein R1 is selected as in (iii) only.
- 22. The compound of claim 18, wherein:
W is hydrogen, C1-4alkyl, benzyl, phenyl, camphoryl, C1-4alkylpiperazinyl or morpholino; X is a direct link, —C(O)—, —OC(O)— or —SO2—; D is nitrogen; R2 is isobutyl or benzyl, or is —CH2CH2SO2CH3; R1 is 4-hydroxybenzyl, 2-phenyleth-1-yl or 4-methoxybenzyl; and J is —CH(CH2Ph)(CONH2), —CH2CH2-(2-pyridyl), —CH2CH2Ph, —CH2CHPh2, —CH2CH2-(1-methyl-3-indolyl) or —CH2CH2-(1-benzyl-3-indolyl).
- 23. The compound of claim 22, where R1 is 2-phenyleth-1-yl or 4-methoxybenzyl.
- 24. The compound of claim 18, wherein:
W is benzyl, phenyl or morpholino; X is a direct link, —C(O)—, —OC(O)— or —SO2—; D is nitrogen; R2 is isobutyl or benzyl; R1 is 2-phenyleth-1-yl or 4-methoxybenzyl; and J is —CH(CH2Ph)(CONH2), —CH2CH2-(2-pyridyl), —CH2CH2Ph, —CH2CHPh2, —CH2CH2-(1-methyl-3-indolyl) or —CH2CH2-(1-benzyl-3-indolyl).
- 25. The compound of claim 18 that is selected from the group consisting of N-(2-phenyl-1-carbamoyl-1-ethyl)-3-((N-benzyloxycarbonyl)-phenylalaninyl)-2-oxo-5-phenylpentanamide, N-(2-(2-pyridyl)-1-ethyl)-3-((N-benzyloxycarbonyl)phenylalaninyl)-2-oxo-4-(4-methoxyphenyl)butanamide, N-(2-phenyl-1-ethyl)-3-((N-benzyloxycarbonyl)cyclohexylalaninyl)-2-oxo-4-(4-methoxyphenyl)butanamide, N-(2-(2-pyridyl)-1-ethyl)-3-((N-benzyloxycarbonyl)leucyl)-2-oxo-4-(4-methoxyphenyl)butanamide, N-(2,2-diphenyl-1-ethyl)-3-((N-benzyloxycarbonyl)phenylalaninyl)-2-oxo-4-(4-methoxyphenyl)butanamide, N-(2-(1-methyl-3-indolyl)-1-ethyl)-3-((N-benzyloxycarbonyl)leucyl)-2-oxo-4-(4-methoxyphenyl)butanamide, N-(2-(1-benzyl-3-indolyl)- 1-ethyl)-3-((N-benzyloxycarbonyl)leucyl)-2-oxo-4-(4-methoxyphenyl)butanamide, N-(2-phenyl- 1-carbamoyl-1-ethyl)-3-((N-morpholinocarbonyl)leucyl)-2-oxo-5-phenylpentanamide, N-(2-phenyl-1-ethyl)-3-((N-benzyloxycarbonyl)leucyl) -2-oxo-4-(4-methoxyphenyl)-butanamide, N-(2-phenyl-1-ethyl)-3-((N-benzyloxycarbonyl)phenylalaninyl)-2-oxo-4-(4-methoxyphenyl)butanamide, N-(2-phenyl-1-ethyl)-3-((N-phenylsulfonyl)leucyl)-2-oxo-4-(4-methoxyphenyl)butanamide and N-(2-phenyl-1-ethyl)-3-((N-phenylsulfonyl)phenylalaninyl)-2-oxo-4-(4-methoxyphenyl)butanamide.
- 26. A compound of formula IV:
- 27. The compound of claim 26, wherein L is heteroaryl or heterocyclyl.
- 28. The compound of claim 26, wherein R1 is selected as in (i) only.
- 29. The compound of claim 26, wherein R1 is selected as in (ii) only.
- 30. The compound of claim 26, wherein:
W is hydrogen, C1-4alkyl, benzyl, phenyl, camphoryl, C1-4alkylpiperazinyl or morpholino; X is a direct link, —C(O)—, —OC(O)— or —SO2—; D is nitrogen; R2 is isobutyl or benzyl, or is —CH2CH2SO2CH3; R1 is 4-hydroxybenzyl, benzyl, 2-phenyleth-1-yl or 4-methoxybenzyl; and L is oxaalkyl or heterocyclyl.
- 31. The compound of claim 26, wherein L is heterocyclyl.
- 32. The compound of claim 26, wherein:
W is C1-4alkyl or benzyl; X is —OC(O)— or —SO2—; D is nitrogen; R2 is isobutyl or benzyl, or is —CH2CH2SO2CH3; R1 is benzyl or 2-phenyleth-1-yl; and L is methoxy or 1-indolinyl.
- 33. The compound of claim 26, wherein W is tert-butyl or benzyl and L is 1-indolinyl.
- 34. The compound of claim 26 selected from the group consisting of methyl (E)-4-((N-(benzyloxycarbonyl)phenylalanyl)amino)-5-phenyl-2-pentenoate, methyl (E)-4-((N-(benzyloxycarbonyl)phenylalanyl)-amino)-6-phenyl-2-hexenoate, N-(1-indolinyl)-(E)-4-((N-(tert-butoxy-carbonyl)phenylalanyl)amino)-6-phenyl-2-hexenamide, N-(1-indolinyl)-(E)-4-((N-(tert-butoxycarbonyl)leucyl)amino)-6-phenyl-2-hexenamide, N-(1-indolinyl)-(E)-4-((N-tert-butoxycarbonyl-S,S-dioxomethioninyl)amino)-6-phenyl-2-hexenoate, N-(1-indolinyl)-(E)-4-((N-(benzylsulfonyl)phenylalanyl)-amino)-6-phenyl-2-hexenamide and N-(1-indolinyl)-(E)-4-((N-(benzyl-sulfonyl)leucyl)amino)-6-phenyl-2-hexenamide.
- 35. A pharmaceutical composition, comprising therapeutially effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
- 36. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 18 in a pharmaceutically acceptable carrier.
- 37. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 26 in a pharmaceutically acceptable carrier.
- 38. An article of manufacture, comprising packaging material, a compound of claim 1 or a pharmaceutically acceptable derivative thereof, which is effective for inhibiting falcipain or cruzain, or for treatment, prevention or amelioration of one or more symptoms of parasitic infections, and a label that indicates that the compound or pharmaceutically acceptable derivative thereof is used for inhibiting falcipain or cruzain, or for treatment, prevention or amelioration of one or more symptoms of parasitic infections.
- 39. An article of manufacture, comprising packaging material, a compound of claim 18 or a pharmaceutically acceptable derivative thereof, which is effective for inhibiting falcipain or cruzain, or for treatment, prevention or amelioration of one or more symptoms of parasitic infections, and a label that indicates that the compound or pharmaceutically acceptable derivative thereof is used for inhibiting falcipain or cruzain, or for treatment, prevention or amelioration of one or more symptoms of parasitic infections.
- 40. An article of manufacture, comprising packaging material, a compound of claim 26 or a pharmaceutically acceptable derivative thereof, which is effective for inhibiting falcipain or cruzain, or for treatment, prevention or amelioration of one or more symptoms of parasitic infections, and a label that indicates that the compound or pharmaceutically acceptable derivative thereof is used for inhibiting falcipain or cruzain, or for treatment, prevention or amelioration of one or more symptoms of parasitic infections.
- 41. A method of inhibiting falcipain, comprising administering a therapeutically effective amount of a compound of claim 1.
- 42. A method of inhibiting falcipain, comprising administering a therapeutically effective amount of a compound of claim 18.
- 43. A method of inhibiting falcipain, comprising administering a therapeutically effective amount of a compound of claim 26.
- 44. A method of inhibiting cruzain, comprising administering a therapeutically effective amount of a compound of claim 1.
- 45. A method of inhibiting cruzain, comprising administering a therapeutically effective amount of a compound of claim 18.
- 46. A method of inhibiting cruzain, comprising administering a therapeutically effective amount of a compound of claim 26.
- 47. A method of treating, preventing, or ameliorating one or more symptoms of parasitic infection, comprising administering a therapeutically effective amount of a compound of claim 1.
- 48. A method of treating, preventing, or ameliorating one or more symptoms of parasitic infection, comprising administering a therapeutically effective amount of a compound of claim 18.
- 49. A method of treating, preventing, or ameliorating one or more symptoms of parasitic infection, comprising administering a therapeutically effective amount of a compound of claim 26.
- 50. A method of inhibiting the development or growth of mammalian parasites, comprising administering a therapeutically effective amount of a compound of claim 1.
- 51. A method of inhibiting the development or growth of mammalian parasites, comprising administering a therapeutically effective amount of a compound of claim 18.
- 52. A method of inhibiting the development or growth of mammalian parasites, comprising administering a therapeutically effective amount of a compound of claim 26.
- 53. A method of inhibiting falcipain, comprising administering a therapeutically effective amount of a compound of formula I:
- 54. A method of inhibiting cruzain, comprising administering a therapeutically effective amount of a compound of formula I:
- 55. A method of treating, preventing, or ameliorating one or more symptoms of parasitic infection, comprising administering a therapeutically effective amount of a compound of formula I:
- 56. A method of inhibiting the development or growth of mammalian parasites, comprising administering a therapeutically effective amount of a compound of formula I:
- 57. A pharmaceutical composition, comprising:
(i) a compound of formula I: 22or a pharmaceutically acceptable derivative thereof, wherein:
W is H, alkyl, alkenyl, alkynyl, oxaalkyl, oxaalkenyl, oxaalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, -alkylcarboxylic acid, -alkenylcarboxylic acid, -alkynylcarboxylic acid, -alkylcarbonylalkyl, -alkenylcarbonylalkenyl, -alkynylcarbonylalkynyl, nitroalkyl, nitroalkenyl, nitroalkynyl, -alkylamine, -alkenylamine, -alkynylamine, -alkylimine, -alkenylimine, -alkynylimine, -alkylamide, -alkenylamide, -alkynylamide, -alkylcarbamoyl, -alkenylcarbamoyl, -alkynylcarbamoyl, -alkylurea, -alkenylurea, -alkynylurea, -alkylhydrazine, -alkenylhydrazine, -alkynylhydrazine, alkylnitrile, alkenylnitrile, alkynylnitrile, alkylazide, alkenylazide, alkynylazide, thioalkyl, thioalkenyl, thioalkynyl, alkylthiol, alkenylthiol, alkynylthiol, alkylisothiol, alkenylisothiol, alkynylisothiol, -alkylthionylalkyl, -alkenylthionylalkenyl, -alkynylthionylalkynyl, -alkylsulfurylalkyl, -alkenylsulfurylalkenyl, -alkynylsulfurylalkynyl, -alkylsulfonic acid, -alkenylsulfonic acid, -alkynylsulfonic acid, -alkylsulfonamide, -alkenylsulfonamide, -alkynylsulfonamide, -alkylphosphonic acid, -alkenylphosphonic acid, -alkynylphosphonic acid, -alkylguanidino, -alkenylguanidino, -alkynylguanidino, -alkyl(N-amidino)piperidine, -alkenyl(N-amidino)piperidine, -alkynyl(N-amidino)piperidine, cycloalkyl, -cycloalkylalkyl, -cycloalkylalkenyl, -cycloalkylalkynyl, -alkylcycloalkyl, -alkenylcycloalkyl, -alkynylcycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaralkyl, unsubstituted or substituted alkylheteroaryl, unsubstituted or substituted heterocyclyl, or unsubstituted or substituted bicycloalkyl, bicycloalkenyl or bicycloalkynyl; X is a direct link, —C(O)—, —OC(O)— or —S(O)n— where n is an integer from 0 to 2; D is nitrogen; R2 is selected from among H, alkyl, alkenyl, alkynyl, oxaalkyl, oxaalkenyl, oxaalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, -alkylcarbonylalkyl, -alkenylcarbonylalkenyl, -alkynylcarbonylalkynyl, -alkylamine, -alkenylamine, -alkynylamine, -alkylamide, -alkenylamide, -alkynylamide, -alkylcarbamoyl, -alkenylcarbamoyl, -alkynylcarbamoyl, -alkylurea, -alkenylurea, -alkynylurea, -alkylsulfurylalkyl, -alkenylsulfurylalkenyl, -alkynylsulfurylalkynyl, -alkylguanidino, -alkenylguanidino, -alkynylguanidino, -alkyl(N-amidino)piperidine, -alkenyl(N-amidino)piperidine, -alkynyl(N-amidino)piperidine, cycloalkyl, -cycloalkylalkyl, -cycloalkylalkenyl, -cycloalkylalkynyl, -alkylcycloalkyl, -alkenylcycloalkyl, -alkynylcycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl, and unsubstituted or substituted heteroaralkyl; E is carbon; R1 is H. alkyl, alkenyl, alkynyl, oxaalkyl, oxaalkenyl, oxaalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, -alkylcarboxylic acid, -alkenylcarboxylic acid, -alkynylcarboxylic acid, -alkylcarbonylalkyl, -alkenylcarbonylalkenyl, -alkynylcarbonylalkynyl, nitroalkyl, nitroalkenyl, nitroalkynyl, -alkylimine, -alkenylimine, -alkynylimine, -alkylamide, -alkenylamide, -alkynylamide, -alkylcarbamoyl, -alkenylcarbamoyl, -alkynylcarbamoyl, -alkylurea, -alkenylurea, -alkynylurea, -alkylhydrazine, -alkenylhydrazine, -alkynylhydrazine, alkylnitrile, alkenylnitrile, alkynylnitrile, alkylazide, alkenylazide, alkynylazide, thioalkyl, thioalkenyl, thioalkynyl, alkylisothiol, alkenylisothiol, alkynylisothiol, -alkylthionylalkyl, -alkenylthionylalkenyl, -alkynylthionylalkynyl, -alkylsulfurylalkyl, -alkenylsulfurylalkenyl, -alkynylsulfurylalkynyl, -alkylsulfonic acid, -alkenylsulfonic acid, -alkynylsulfonic acid, -alkylsulfonamide, -alkenylsulfonamide, -alkynylsulfonamide, -alkylphosphonic acid, -alkenylphosphonic acid, -alkynylphosphonic acid, -alkylguanidino, -alkenylguanidino, -alkynylguanidino, -alkyl(N-amidino)piperidine, -alkenyl(N-amidino)piperidine, -alkynyl(N-amidino)piperidine, cycloalkyl, -cycloalkylalkyl, -cycloalkylalkenyl, -cycloalkylalkynyl, -alkylcycloalkyl, -alkenylcycloalkyl, -alkynylcycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl, or unsubstituted or substituted heteroaralkyl; Y is —C(O)—, —A′H═CHC(O)— or —A′(O)C(O)NH— where A′ is carbon; and Z is G, J or L where G is hydrogen; and J and L are each independently selected from among H, alkyl, alkenyl, alkynyl, oxaalkyl, oxaalkenyl, oxaalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, -alkylcarboxylic acid, -alkenylcarboxylic acid, -alkynylcarboxylic acid, -alkylcarbonylalkyl, -alkenylcarbonylalkenyl, -alkynylcarbonylalkynyl, nitroalkyl, nitroalkenyl, nitroalkynyl, -alkylamine, -alkenylamine, -alkynylamine, -alkylimine, -alkenylimine, -alkynylimine, -alkylamide, -alkenylamide, -alkynylamide, -alkylcarbamoyl, -alkenylcarbamoyl, -alkynylcarbamoyl, -alkylurea, -alkenylurea, -alkynylurea, -alkylhydrazine, -alkenylhydrazine, -alkynylhydrazine, alkylnitrile, alkenylnitrile, alkynylnitrile, alkylazide, alkenylazide, alkynylazide, thioalkyl, thioalkenyl, thioalkynyl, alkylthiol, alkenylthiol, alkynylthiol, alkylisothiol, alkenylisothiol, alkynylisothiol, -alkylthionylalkyl, -alkenylthionylalkenyl, -alkynylthionylalkynyl, -alkylsulfurylalkyl, -alkenylsulfurylalkenyl, -alkynylsulfurylalkynyl, -alkylsulfonic acid, -alkenylsulfonic acid, -alkynylsulfonic acid, -alkylsulfonamide, -alkenylsulfonamide, -alkynylsulfonamide, -alkylphosphonic acid, -alkenylphosphonic acid, -alkynylphosphonic acid, -alkylguanidino, -alkenylguanidino, -alkynylguanidino, -alkyl(N-amidino)piperidine, -alkenyl(N-amidino)piperidine, -alkynyl(N-amidino)piperidine, cycloalkyl, -cycloalkylalkyl, -cycloalkylalkenyl, -cycloalkylalkynyl, -alkylcycloalkyl, -alkenylcycloalkyl, -alkynylcycloalkyl, alkylamino, arylamino, dialkylamino, (alkyl)(aryl)amino, diarylamino, heteroarylamino, diheteroarylamino, (alkyl)(heteroaryl)amino, (aryl)(heteroaryl)amino, amino, heteroaryl or heterocyclyl; with the provisos that (i) if Y is —C(O)— or —A′(O)C(O)NH, then R1 is not hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, -alkylamino, -alkenylamine, -alkynylamine, alkylthiol, alkenylthiol or alkynylthiol; (ii) if X is —OC(O)—, then D is not attached ot oxygen; (iii) if Y is —C(O)—, then Z is G; (iv) if Y is —A′H═CHC(O)—, then Z is J; (v) if Y is —A′(O)C(O)NH—, then Z is L; and/or (vi) is Y is —A′H═CHC(O)— or —A′(O)C(O)NH—, then E is attached to A′; and (ii) an antiparasitic compound or composition.
- 58. The composition of claim 57, wherein the antiparasitic compound or composition is selected from the group consisting of chloroquine, quinine, quinidine, amodiaquine, mefloquine, sulfadoxine, pyrimethamine, a tetracyline antibiotic, clindamycin, a sulfa antibiotic, doxycyline, proguanil, dapsone, primaquine, artemisinin, artesunate, artelinate, artemether, arteether, dihydroartemisinin, halofantrine, atovaquione, pyronaridine, desferrioxamine, azithromycin, SC-50083, Ro 40-4388, “compound 7”, ((benzyloxycarbonyl)phenylalanyl)arginyl fluoromethyl ketone, ((morpholinocarbonyl)phenylalanyl)homophenylalanyl fluoromethyl ketone, (((morpholinocarbonyl)leucyl)homophenylalanyl)vinyl phenyl sulfone, oxalic bis((2-hydroxy-1-naphthylmethylene)hydrazide), 1-(2,5-dichlorophenyl)-3-(4-quinolinyl)-2-propen-1-one,and 7-chloro-1,2-dihydro-2-(2,3-dimethoxyphenyl)-5,5-dioxide-4-(1H, 10H)-phenothiazinone.
- 59. The composition of claim 57, wherein the antiparasitic compound of composition is selected from the group consisting of nifurtimox, benznidazole, (((morpholinocarbonyl)phenylalanyl)homophenylalanyl)vinyl phenyl sulfone, (((morpholinocarbonyl)phenylalanyl)-lysyl)vinyl phenyl sulfone, (((morpholinocarbonyl)phenylalanyl)valyl)vinyl phenyl sulfone, (((morpholinocarbonyl)phenylalanyl)-O-benzylseryl)vinyl phenyl sulfone, (((morpholinocarbonyl)leucyl)homophenylalanyl)vinyl phenyl sulfone, (((morpholinocarbonyl)tyrosyl)homophenylalanyl)vinyl phenyl sulfone, (((tert-butoxycarbonyl)-2-tetrahydroisoquinolylcarbonyl)-homophenylalanyl) phenyl vinyl sulfone, (((morpholinocarbonyl)tyrosyl)-homophenylalanyl)vinyl phenyl sulfone, (((morpholinocarbonyl)phenyl-alanyl)homophenylalanyl fluromethylketone and (((morpholinocarbonyl)-phenylalanyl)homophenylalanyl)valine benzylamide.
- 60. A method of inhibiting falcipain, comprising administering a therapeutically effective amount of a composition of claim 57.
- 61. A method of inhibiting cruzain, comprising administering a therapeutically effective amount of a composition of claim 57.
- 62. A method of treating, preventing, or ameliorating one or more symptoms of parasitic infection, comprising administering a therapeutically effective amount of a composition of claim 57.
- 63. A method of inhibiting the development or growth of mammalian parasites, comprising administering a therapeutically effective amount of a composition of claim 57.
- 64. An article of manufacture, comprising packaging material, a composition of claim 57, which is effective for inhibiting falcipain or cruzain, or for treatment, prevention or amelioration of one or more symptoms of parasitic infections, and a label that indicates that the composition is used for inhibiting falcipain or cruzain, or for treatment, prevention or amelioration of one or more symptoms of parasitic infections.
RELATED APPLICATIONS
[0001] Benefit of priority is claimed under 35 U.S.C. §119(e) to U.S. application Ser. No. 60/255,221, filed Dec. 12, 2000, to Lim-Wilby et al., entitled “COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS.” The disclosure of the above-referenced application is incorporated by reference herein in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60255221 |
Dec 2000 |
US |